Henry Schein

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial on a non-recourse basis, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Henry Schein reports solid Q4 performance and anticipates growth

Henry Schein's Q4 performance showcased growth amidst challenges, with a strategic focus on core margin expansion and strong performance in dental specialties. While facing challenges from declining PPE sales and supply chain issues, the company sees opportunities in stable dental markets and continued growth in operating income. Overall, the company remains optimistic about its outlook for 2023.

Henry Schein reports strong Q1 earnings, eyes growth through acquisitions

Henry Schein's Q1 2023 earnings call highlighted strong financial performance across its dental, medical, and Technology and Value-Added Services businesses. While facing challenges from declining PPE and COVID-19 test kit sales, the company remains optimistic about growth opportunities through acquisitions and stable business segments.

Henry Schein reports solid Q2 results, eyes growth opportunities

Henry Schein's Q2 performance was driven by strong dental sales, while facing challenges from declining PPE and COVID test kit sales. The company is focused on strategic acquisitions and expanding product offerings, with opportunities in technology and specialty products driving growth.

Henry Schein navigates post-cyber incident challenges, focuses on recovery

Henry Schein faced challenges from a cybersecurity incident impacting operations but showcased resilience and recovery efforts across its business segments.
Strategic initiatives focused on customer retention, operational efficiency, and cybersecurity response highlight the company's commitment to long-term growth and stability.
Despite challenges in specific segments and cybersecurity spending variables, Henry Schein's focus on recovery, cost-cutting, and customer trust positions it for future opportunities.
The company's emphasis on digital channels, stable medical demand, and strategic cost-cutting measures underscores its adaptability and strategic vision for sustained growth.

Henry Schein reports resilient Q4 performance and outlines 2024 guidance

Henry Schein's Q4 2023 performance reflects resilience amidst challenges, with a strategic focus on technology, global sales, and recovery post-cyber incident. The company's 2024 outlook includes managing residual cyber impacts and pursuing growth opportunities.

Henry Schein reports solid Q1 earnings, eyes market share expansion

Henry Schein's Q1 performance reflects resilience and growth across key segments, with a focus on market share expansion and profitability. While facing challenges in dental consumables and pricing stability, the company is leveraging opportunities in product portfolio expansion and market positioning. Strategic acquisitions and recovery efforts post-cyber incident are driving competitive strength and customer loyalty.

Henry Schein reports mixed Q2 performance, focuses on cost savings

Henry Schein navigated challenges from a cyber incident, with mixed performance across segments in Q2 2024.
Strong sales growth in dental specialties, focus on cost savings, and resilience in technology services were highlights.
The company's strategic initiatives, financial guidance update, and confidence in future prospects were key takeaways from the call.

Henry Schein excels in Q3 with strategic growth initiatives

Henry Schein's Q3 performance reflects strong market positioning and strategic execution, driving growth across key business segments.
While facing challenges such as LCI sales decline, the company's focus on operational efficiency and cost management remains a priority.
With increased sales guidance, ongoing restructuring initiatives, and strategic capital allocation plans, Henry Schein is poised for continued success and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Insulet

Zimmer Biomet Hlds

Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.

Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More

Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Henry Schein (HSIC) Expected to Beat Earnings Estimates: Should You Buy? (Revised)

The robust performance of the Primescan system in Europe and the United States is expected to have contributed to Henry Schein's (HSIC) top line during Q3.

Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

Why Is Henry Schein (HSIC) Down 2.2% Since Last Earnings Report?

Patterson Companies

DENTSPLY SIRONA

Dental practice management software helps dental businesses run smoothly by ensuring safe storage and easy access of critical information.

3 Best Dental Stocks to Keep An Eye On

The platform is expected to augment Henry Schein's (HSIC) patient revenues, accelerate payments and curb collection costs.

Henry Schein Expands SolutionsHub With CueSquared MobilePay

Let's see if Henry Schein (HSIC) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Pick Henry Schein (HSIC) Stock Now?

Henry Schein, Inc. (HSIC) CEO Stanley Bergman on Q2 2019 Results - Earnings Call Transcript

Henry Schein (HSIC) sees solid performance by the global Medical and Technology and Value-added Services businesses in Q2.

Henry Schein (HSIC) Q2 Earnings Beat Estimates, Revenues Miss

Henry Schein (HSIC) is working diligently to grow in the field of digital dentistry, globally.

Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?

The Elite Computer acquisition marks Henry Schein's (HSIC) foray into the Italian dental practice management software market.

Henry Schein Closes Acquisition of Elite Computer Italia

West Pharmaceutical Services

HSIC vs. WST: Which Stock Is the Better Value Option?

HSIC vs. WST: Which Stock Should Value Investors Buy Now?

Why Is Henry Schein (HSIC) Down 1.6% Since Last Earnings Report?

Dean Foods

SolarEdge Technologies

See how these three stocks resisted the broader market's decline.

Why Henry Schein, Dean Foods, and SolarEdge Jumped Today

Henry Schein, Inc. (HSIC) CEO Stanley Bergman on Q1 2019 Results - Earnings Call Transcript

Henry Schein's (HSIC) strong share gains in the North American market raise optimism.

Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates

Henry Schein (HSIC) delivered earnings and revenue surprises of 5.26% and 0.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Q1 Earnings and Revenues Beat Estimates

Henry Schein (HSIC) is consistently riding on segmental strength at Dental, Medical and Technology plus Value-Added Services.

Can Dental Growth Drive Henry Schein's (HSIC) Q1 Earnings?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Henry Schein (HSIC) Up 2.1% Since Last Earnings Report?

Henry Schein expects the acquisition to be neutral to its 2019 earnings per diluted share and accretive thereafter.

News for Henry Schein Stock (HSIC)